{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"1988 FIGO Stage correlation with progression-free survival for patients on study treatment.","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Hazard Ratio (HR)","paramValue":"0.207","statisticalMethod":"Cox Proportional Hazards","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"}]}],"title":"FIFO Stage I"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"FIGO Stage II"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"FIGO Stage III"}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"}],"units":"Participants"}],"description":"Stage I: confined to the uterine corpus Stage II: confined to corpus and cervix Stage IIIA: serosa involvement only (disease could involve the uterine serosa, but patients must have had no other evidence of local spread)","groups":[{"id":"OG000","title":"Women Treated With Adjuvant Regimen for High Risk Uterine LMS"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Correlation Between 1988 FIGO Stage and Tumor Response to Treatment (PFS)","type":"SECONDARY","unitOfMeasure":"participants"}